Rigel Announces Third Quarter 2009 Financi...(ands except per share amounts) ...),Health

Date:11/3/2009

ands, except per share amounts) Three Months Ended Nine Months Ended September 30, September 30, 2009 2008 2009 2008 ---- ---- ---- ---- (unaudited) (unaudited) Revenues: Contract revenues $- $- $- $- Operating expenses: Research and development (see Note A) 21,082 31,232 70,568 81,268 General and administrative (see Note A) 5,573 7,450 15,226 21,436 Restructuring charges (see Note A) - - 1,141 - --- --- ----- --- Total operating expenses 26,655 38,682 86,935 102,704 ------ ------ ------ ------- Loss from operations (26,655) (38,682) (86,935) (102,704) Interest income, net 4 991 388 3,722 --- --- --- ----- Loss before income taxes (26,651) (37,691) (86,547) (98,982) Income tax benefit - - 93 - --- --- --- --- Net loss $(26,651) $(37,691) $(86,454) $(98,982) ======== ======== ======== ======== Net loss per share, basic and diluted $(0.70) $(1.03) $(2.32) $(2.76) ====== ====== ====== ====== Weighted average shares used in computing net loss per share, basic and diluted
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Rigel Announces Presentations at Two Investor Conferences
2. Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
3. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
4. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
5. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
6. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
7. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
8. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
9. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
10. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
11. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders